Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?
1 Translational Research Laboratoryatalan Institute of Oncology, Hospital Germans Trias i Pujol, 08916 Barcelona, Badalona, Spain ; 2 Fundación Clínica, Médica Sur. Puente de piedra 150, Col Toriello Guerra, 14050 Mexico City, Mexico ; 3 Carcinogenesis laboratory, National Cancer Institute, Col. Sección XVI, 14080 Mexico City, México ; 4 Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, 08916 Badalona, Barcelona, Spain ; 5 Molecular Oncology Research (MORe) Foundation, C/Sabino Arana 5-19, 08028 Barcelona, Spain.
Daniela
D
Morales-Espinosa
1 Translational Research Laboratoryatalan Institute of Oncology, Hospital Germans Trias i Pujol, 08916 Barcelona, Badalona, Spain ; 2 Fundación Clínica, Médica Sur. Puente de piedra 150, Col Toriello Guerra, 14050 Mexico City, Mexico ; 3 Carcinogenesis laboratory, National Cancer Institute, Col. Sección XVI, 14080 Mexico City, México ; 4 Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, 08916 Badalona, Barcelona, Spain ; 5 Molecular Oncology Research (MORe) Foundation, C/Sabino Arana 5-19, 08028 Barcelona, Spain.
Rafael
R
Rosell